{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/multiple-myeloma/management/confirmed-multiple-myeloma/","result":{"pageContext":{"chapter":{"id":"c51edfd3-b143-5dfe-b734-2f46b572a5de","slug":"confirmed-multiple-myeloma","fullItemName":"Scenario: Confirmed multiple myeloma","depth":2,"htmlHeader":"<!-- begin field 3c049156-00e6-4140-b764-d80feac314de --><h2>Scenario: Confirmed multiple myeloma</h2><!-- end field 3c049156-00e6-4140-b764-d80feac314de -->","summary":"Covers the management of a person with a confirmed diagnosis of multiple myeloma, including pain management and self-care advice.","htmlStringContent":"<!-- begin item 2f1c9809-4e0f-4f14-9f6e-fd46b95e1565 --><!-- begin field 8ff13246-5eee-4bf1-b17e-acd900adf522 --><p>From age 18 years onwards.</p><!-- end field 8ff13246-5eee-4bf1-b17e-acd900adf522 --><!-- end item 2f1c9809-4e0f-4f14-9f6e-fd46b95e1565 -->","topic":{"id":"a3257bde-777f-5b48-80cd-28a6de5401b7","topicId":"d449062b-fe98-40a2-bc4d-741f0b91c31d","topicName":"Multiple myeloma","slug":"multiple-myeloma","lastRevised":"Last revised in January 2021","chapters":[{"id":"001bce70-f61f-5905-b9a0-76e49dc2928b","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a4e4ac31-e5c3-5d0d-ba8e-e28d748b38a8","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"d731856b-56b9-5d81-9db1-6e0380152383","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"288251ee-9e56-550b-bb07-75c191dd88bb","slug":"changes","fullItemName":"Changes"},{"id":"972750f6-1493-51ac-bb67-61a883caef31","slug":"update","fullItemName":"Update"}]},{"id":"9ee3d2ca-5de2-5a81-be8d-5389cb6b96fb","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"02fc2e8c-0154-52e2-81b7-13f9f7ae4157","slug":"goals","fullItemName":"Goals"},{"id":"297bf476-1f3c-5477-859b-fc44c3d58cdd","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ca441620-7e21-5b08-9340-cca6210d21e9","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"23d46a0d-5d23-5d38-a2d7-817babead45a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7f4644ec-a108-52f6-874b-8644bd8da047","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c6fdac6a-e178-59a4-bcb7-a22337d627a4","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"c45f4611-e831-51b1-ae27-0421b247f510","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"7e70c907-9e94-5f79-b9bb-ba6799a19ccd","slug":"definition","fullItemName":"Definition"},{"id":"64fa3b9a-e0f1-5f2c-aa6b-99ca7f657bb9","slug":"prevalence","fullItemName":"Prevalence"},{"id":"222268d1-82ef-5947-9a94-81c9475bd101","slug":"risk-factors","fullItemName":"Risk Factors"},{"id":"f2cd915a-2200-5a59-9f4b-e92d4e9721d6","slug":"prognosis","fullItemName":"Prognosis"},{"id":"b84e32aa-3d7d-5e4b-a3d8-9c8cc506b4a9","slug":"complications","fullItemName":"Complications"}]},{"id":"cd2396e2-8290-5f66-ad0f-871bfebc83dd","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d1d186e7-f167-55b0-a9ba-20bc6df07ce9","slug":"when-should-i-suspect-multiple-myeloma","fullItemName":"When should I suspect multiple myeloma?"},{"id":"8116b468-694e-5fa4-aa60-09f23bc088e0","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"46717c89-6886-52dc-8e80-d8fb592c32b2","fullItemName":"Management","slug":"management","subChapters":[{"id":"da1a6baa-3eff-5249-bb76-6d086063c369","slug":"suspected-multiple-myeloma","fullItemName":"Scenario: Suspected multiple myeloma"},{"id":"c51edfd3-b143-5dfe-b734-2f46b572a5de","slug":"confirmed-multiple-myeloma","fullItemName":"Scenario: Confirmed multiple myeloma"},{"id":"1544f647-8ce2-51e4-adee-9cb61fc46ae1","slug":"end-stage-multiple-myeloma","fullItemName":"Scenario: End-stage multiple myeloma"}]},{"id":"375c8b98-56b6-5c85-a182-36856a3db2ca","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"b088260f-8cf4-5102-b99d-ab78d3ac71d3","slug":"analgesia","fullItemName":"Analgesia"}]},{"id":"ddabb890-df48-5057-a56f-32666fa74e9a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"9764188e-1795-5b4f-8cdf-b70befc3fe0d","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"aef9e65b-4f13-546f-adbc-19654498aa31","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"79a1401a-ca39-5eff-ab8b-482281e9741f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b84ca8eb-2866-56cb-b7a1-ecb59575fddc","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"592f1670-1381-587b-baec-8618a8caf851","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e6e2cada-c7c4-5f01-bf87-9cecee0c53f0","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"6b485c3d-36d7-556a-993b-3311a38b7bf6","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"46717c89-6886-52dc-8e80-d8fb592c32b2","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"c01031b9-9219-5dff-8613-773fec2820b1","slug":"how-should-i-manage-a-person-with-confirmed-multiple-myeloma","fullItemName":"How should I manage a person with confirmed multiple myeloma?","depth":3,"htmlHeader":"<!-- begin field df281110-703f-472a-a2bb-4d81d4b113d1 --><h3>How should I manage a person with confirmed multiple myeloma?</h3><!-- end field df281110-703f-472a-a2bb-4d81d4b113d1 -->","summary":null,"htmlStringContent":"<!-- begin item 79d83ea2-8411-40ca-8de5-e258d41f6585 --><!-- begin field 96d15a09-716b-4e83-b6c1-1e4d3140791d --><ul><li><strong>People with confirmed multiple myeloma should be treated in secondary care</strong> by a haematologist and a multidisciplinary team that may include oncologists, psychological support services, physiotherapists, occupational therapists, dietitians, adult social care, dental services, and critical and palliative care physicians.<ul><li>People with symptomatic (active) multiple myeloma should be reviewed by a haematologist at least every 3 months, depending on risk factors for progression of the disease.</li><li>People with asymptomatic ('smouldering') multiple myeloma should be reviewed every 3 months for the first 5 years of the disease, with the frequency thereafter depending on the long-term stability of the disease.</li></ul></li><li><strong>The role of primary care may include:</strong><ul><li><strong>Ensuring that infections are treated promptly</strong> with a broad-spectrum antibiotic, in line with local protocols and/or Public Health England guidance.<ul><li>Aminoglycosides should be avoided wherever possible due to risk of renal toxicity.</li></ul></li><li><strong>Pain assessment and management </strong>— if the person reports bone pain:<ul><li>Consider possible <a class=\"topic-reference internal-reference\" href=\"/topics/multiple-myeloma/background-information/complications/\">complications</a> of myeloma including fracture.</li><li>Where appropriate, advise use of paracetamol and/or codeine if tolerated and not contraindicated. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/\">Analgesia - mild-to-moderate pain</a>. Nonsteroidal anti-inflammatory drugs are not recommended due to the risk of renal toxicity.</li><li>In older people, consider comorbidities such as osteoarthritis or osteoporosis mimicking bony malignant pain. For more details see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/osteoarthritis/\">Osteoarthritis</a>.</li><li>If pain persists despite simple analgesia seek specialist advice.</li></ul></li><li><strong>Ensuring that the person has been offered annual vaccination against seasonal influenza and the one-off pneumococcal vaccination.</strong><ul><li>For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/immunizations-seasonal-influenza/\">Immunizations - seasonal influenza</a> and <a class=\"topic-reference external-reference\" href=\"/topics/immunizations-pneumococcal/\">Immunizations – pneumococcal</a>.</li></ul></li><li><strong>Assessing the person for signs of depression and anxiety.</strong><ul><li>For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/depression/\">Depression</a> and <a class=\"topic-reference external-reference\" href=\"/topics/generalized-anxiety-disorder/\">Generalized anxiety disorder</a>.</li></ul></li><li><strong>Offering advice and information to the person and their family/carers on:</strong><ul><li>The disease process, relapse and remission cycle, and the person's overall prognosis.</li><li>Symptoms of myeloma and treatment-related adverse effects (including corticosteroid-related side effects, neuropathy, deep vein thrombosis, and bisphosphonate-related osteonecrosis of the jaw).</li><li>Lifestyle measures to optimize bone health and renal function, such as exercise and maintaining adequate hydration.</li><li>Identifying and reporting new symptoms, such as pain, symptoms of spinal cord compression, and symptoms of infection.</li><li>The role of supportive and palliative care.</li><li>End of life issues.</li></ul></li><li><strong>Providing sources of information and self-help such as:</strong><ul><li><a href=\"https://www.gov.uk/dla-disability-living-allowance-benefit\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"6f728800-d7fb-4760-ad92-acb800f9bd7e\">Disability Living Allowance</a>, <a href=\"https://www.gov.uk/pip\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"c03de17d-1c18-468e-8e0d-acb800f9bd7e\">Personal Independence Payment</a>, and other appropriate social services.</li><li>Patient support groups such as <a href=\"https://www.myeloma.org.uk/\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"aa479bd2-9643-414a-9200-acb800f9bd7e\">Myeloma UK</a> and <a href=\"https://www.macmillan.org.uk/\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"124101b8-43bf-466f-a3ae-acb800f9bd7e\">Macmillan Cancer Support</a>.</li></ul></li></ul></li></ul><!-- end field 96d15a09-716b-4e83-b6c1-1e4d3140791d --><!-- end item 79d83ea2-8411-40ca-8de5-e258d41f6585 -->","subChapters":[{"id":"800e7689-e720-5c8b-b5e3-c207524707fe","slug":"secondary-care-treatments","fullItemName":"Secondary care treatments","depth":4,"htmlHeader":"<!-- begin field 943aa559-48a3-4196-8d19-58465036227d --><h4>Secondary care treatments</h4><!-- end field 943aa559-48a3-4196-8d19-58465036227d -->","summary":null,"htmlStringContent":"<!-- begin item e3908193-3c80-499c-bb47-03fe1eea37c1 --><!-- begin field 0bb4da49-0d79-4df6-af86-0394b6c31f8c --><ul><li><strong>Treatments for multiple myeloma in secondary care depend on the person's age, disease stage, prognosis, and comorbidities, and may include:</strong><ul><li>Bisphosphonates to reduce bone disease and pain such as zolendronic acid, disodium pamidronate, or sodium clodronate.</li><li>Treatments for anaemia such as erythropoietin analogues or blood transfusion.</li><li>Chemotherapeutic drugs such as cyclophosphamide, doxirubicin, carfilozmib, bortezomib, and melphalan.</li><li>Corticosteroids such as dexamethasone and prednisolone.</li><li>Immunomodulatory drugs such as thalidomide, lenalidomide, and pomalidomide.</li><li>High-dose drug therapy and stem cell transplant.</li><li>Deep vein thrombosis prophylaxis (for people taking immunomodulatory drugs) such as aspirin and low molecular weight heparins.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Snowden, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Bingham, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Mhaskar, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Moreau, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">BMJ Best Practice, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">NICE, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Bird, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Guzdar, 2020</a>]</p><!-- end field 0bb4da49-0d79-4df6-af86-0394b6c31f8c --><!-- end item e3908193-3c80-499c-bb47-03fe1eea37c1 -->","subChapters":[]},{"id":"5ca30472-4114-50fc-abac-73bcee4ddf8a","slug":"basis-for-recommendation-0d2","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 121086f6-d49f-4b57-a7d3-14324d2239de --><h4>Basis for recommendation</h4><!-- end field 121086f6-d49f-4b57-a7d3-14324d2239de -->","summary":null,"htmlStringContent":"<!-- begin item 0d29328b-2230-416a-b0a3-30bdbf2b52ee --><!-- begin field 8bd2af9c-c2d8-46c8-b0d0-88ffaa9f212a --><p>The recommendations on management of a person with confirmed multiple myeloma are based on clinical guidelines <em>Myeloma: diagnosis and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">NICE, 2018</a>], <em>Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Moreau, 2017</a>], <em>Guidelines for screening and management of late and long‐term consequences of myeloma and its treatment</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Snowden, 2017</a>], <em>Guidelines for the diagnosis and management of multiple myeloma</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Bird, 2014</a>], the British Committee for Standards in Haematology (BCSH) guideline <em>Supportive care in multiple myeloma</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Snowden, 2011</a>], expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Mhaskar, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">BMJ Best Practice, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Bird, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Guzdar, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/multiple-myeloma/references/\">Herget, 2020</a>], and the expert opinion of an external reviewer of this CKS topic.</p><!-- end field 8bd2af9c-c2d8-46c8-b0d0-88ffaa9f212a --><!-- end item 0d29328b-2230-416a-b0a3-30bdbf2b52ee -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}